True

doi:10.1038/sj/leu/2401408

Cited by 3 publications

(2 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the clinical relevance of CEACAM6 expression in relation to adverse outcomes and predictive biomarker status related to treatment resistance are yet to be described in B-ALL. CEACAM6 expression in the cytoplasm of multiple human leukemic cell lines is present irrespective of its cell surface expression [60]. Most leukemia tend to have deregulated levels of CEACAM 6 and 8.…”

Section: Ceacam6 Biology Expression and Prognostic Implications In mentioning

confidence: 99%

Emerging Role and Targeting of Carcinoembryonic Antigen-related Cell Adhesion Molecule 6 (CEACAM6) in Human Malignancies

Johnson

Mahadevan²

2015

CCAND

View full text Add to dashboard Cite

Background: Carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) is a member of the CEA family of cell adhesion proteins that belong to the immunoglobulin superfamily. CEACAM6 is normally expressed on the surface of myeloid (CD66c) and epithelial surfaces. Stiochiomertic expression of members of the CEA family (CEACAM1, 5, 6, 7) on epithelia maintains normal tissue architecture through homo-and hetero-philic interactions. Dysregulated over-expression of CEACAM6 is oncogenic, is associated with anoikis resistance and an invasive phenotype mediated by excessive TGFβ, AKT, FAK and SRC signaling in human malignancies. Methods: Extensive literature review through PubMed was conducted to identify relevant preclinical and clinical research publications regarding CEACAM6 over the last decade and was summarized in this manuscript. Results: CEACAM5 and 6 are over-expressed in nearly 70% of epithelial malignancies including colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDA), hepatobiliary, gastric, breast, non-small cell lung and head/neck cancers. Importantly, CEACAM6 is a poor prognostic marker in CRC, while its expression correlates with tumor stage, metastasis and post-operative survival in PDA. CEACAM6 appears to be an immune checkpoint suppressor in hematologic malignancies including acute lymphoblastic leukemia and multiple myeloma. Several therapeutic monoclonal antibodies or antibody fragments targeting CEACAM6 have been designed and developed as a targeted therapy for human malignancies. A Llama antibody targeting CEACAM6 is being evaluated in early phase clinical trials. Conclusion: This review focuses on the role of CEACAM6 in the pathogenesis and signaling of the malignant phenotype in solid and hematologic malignancies and highlights its potential as a therapeutic target for anti-cancer therapy.

show abstract

Section: Ceacam6 Biology Expression and Prognostic Implications In mentioning

confidence: 99%

Emerging Role and Targeting of Carcinoembryonic Antigen-related Cell Adhesion Molecule 6 (CEACAM6) in Human Malignancies

Johnson

Mahadevan²

2015

CCAND

View full text Add to dashboard Cite

show abstract

“…43, 130 CD66c (KOR-SA3544) has also been reported to be preferentially expressed in BCR-ABL fusion gene and in hyperdiploid BCP-ALL cases. 131, 132, 133 Given the potential impact of CD66c, the antibody was placed in the strong PE channel. MLL -rearranged cases generally show a CD19 + /CD34 + /NuTdT + /CD10 − /CD15 +/− /CD65 +/− /CD9 + /CD24 −/partially+ immunophenotype 134, 135 with characteristic expression of NG2, although this is not specific.…”

Section: Introductionmentioning

confidence: 99%

EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes

et al. 2012

View full text Add to dashboard Cite

Most consensus leukemia & lymphoma antibody panels consist of lists of markers based on expert opinions, but they have not been validated. Here we present the validated EuroFlow 8-color antibody panels for immunophenotyping of hematological malignancies. The single-tube screening panels and multi-tube classification panels fit into the EuroFlow diagnostic algorithm with entries defined by clinical and laboratory parameters. The panels were constructed in 2–7 sequential design–evaluation–redesign rounds, using novel Infinicyt software tools for multivariate data analysis. Two groups of markers are combined in each 8-color tube: (i) backbone markers to identify distinct cell populations in a sample, and (ii) markers for characterization of specific cell populations. In multi-tube panels, the backbone markers were optimally placed at the same fluorochrome position in every tube, to provide identical multidimensional localization of the target cell population(s). The characterization markers were positioned according to the diagnostic utility of the combined markers. Each proposed antibody combination was tested against reference databases of normal and malignant cells from healthy subjects and WHO-based disease entities, respectively. The EuroFlow studies resulted in validated and flexible 8-color antibody panels for multidimensional identification and characterization of normal and aberrant cells, optimally suited for immunophenotypic screening and classification of hematological malignancies.

show abstract

Immunophenotyping of Acute Leukaemias. Immunophänotypisierung akuter Leukämien

Benter¹,

Ratei²,

Wd³

2001

LaboratoriumsMedizin

View full text Add to dashboard Cite

For nearly 100 years the classification of blood cells and the diagnosis of leukaemia have been based on cytomorphological features after staining. Even in the era of molecular biology this is still essential. Therapy of acute myeloid leukaemia (AML) is mostly dependent on the interpretation of the morphological appearance of blasts under the microscope. Cytomorphology should also lead to a rational use of techniques like immunophenotyping, cytogenetics, fluorescence / situ hybridisation (FISH), and polymerase chain reaction (PCR).In the past two decades, the impact of immunophenotyping by flow cytometry in the diagnosis and management of acute leukaemia has expanded rapidly. This has been mainly attributed to significant advances in laser and computer technologies and the production of several hundred monoclonal antibodies (moAbs) to a variety of antinens expressed by haematopoietic cells.This review concentrates on immunophenotyping of cells from patients with acute leukaemia and shows the clinical impact on diagnostics and treatment.

show abstract

True

Cited by 3 publications

References 12 publications

Emerging Role and Targeting of Carcinoembryonic Antigen-related Cell Adhesion Molecule 6 (CEACAM6) in Human Malignancies

Emerging Role and Targeting of Carcinoembryonic Antigen-related Cell Adhesion Molecule 6 (CEACAM6) in Human Malignancies

EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes

Immunophenotyping of Acute Leukaemias. Immunophänotypisierung akuter Leukämien

Contact Info

Product

Resources

About